News Quantified

Stock Stats

News Stats


All News	{{AllNewsCount}}
News Wires	{{NewsWiresCount}}
Media Monitoring	{{MoreOverCount}}
SEC Edgar Filings	{{SecEdgarFilingsCount}}
Upgrades	{{UpgradesCount}}
Downgrades	{{DowngradesCount}}
Initiated	{{InitiatesCount}}
Reiterated	{{ReiteratesCount}}
Last Earnings	{{LastEarnings}}
Last Earnings EPS	{{LastEps}}
Next Earnings	{{NextEarnings}}

Order Stats

Sub-Penny
{{SubPennyStr}}
Odd Lot
{{OddLotStr}}
Avg. bid-ask spread

{{GetAvgBidAskSpreadForScale}}
Avg. bid / ask size
{{GetAvgBidSizeForScale}} {{GetAvgAskSizeForScale}}

Shares at ask / bid
{{SharesAtAsk_AMP_Str}} {{SharesAtBid_AMP_Str}}
Off exchange
{{OffExchange}}

News

Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis

Evommune (NYSE:EVMN) is now covered by analysts at Weiss Ratings. They set a "sell (e)" rating on the stock.

Evommune (NYSE:EVMN) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $42.00 price target on the stock.

Evommune (NYSE:EVMN) was upgraded by analysts at The Goldman Sachs Group, Inc. to a "buy" rating.

Evommune (NYSE:EVMN) was given a new $40.00 price target on by analysts at Raymond James Financial, Inc..

Oppenheimer Holdings, Inc.

Form 8-K Evommune, Inc. For: Feb 10

Form 4 Evommune, Inc. For: Dec 19 Filed by: Hopfner Robert Lorne

Form 4 Evommune, Inc. For: Dec 08 Filed by: Bauer Eugene

Form 4 Evommune, Inc. For: Dec 09 Filed by: Pena Luis C.

Form 4 Evommune, Inc. For: Dec 09 Filed by: Moss Gregory S.

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}